drugset / Trial / NCT07249073
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Phase 0
Recruiting
9 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Hebei Taihe Chunyu Biotechnology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
1. Objective to evaluate the safety and tolerability of CAR19-BCMA dual-target CAR-T in the treatment of relapsed / refractory multiple myeloma. 2. To determine the maximum tolerated dose (MTD) of car19-bcma dual target car-t in the treatment of relapsed / refractory multiple myeloma.
Timeline
- Start
- 2025-03-28
- Primary completion
- 2028-03-27
- Completion
- 2029-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR19-BCMA dual-target CAR-T | Cell therapy | 1e+06 cells/kg | — |
| Subject | CAR19-BCMA dual-target CAR-T | Cell therapy | 2e+06 cells/kg | — |
| Subject | CAR19-BCMA dual-target CAR-T | Cell therapy | 3e+06 cells/kg | — |